Name : Mrs.

SONAL UH ID :
Lab ID : 26210002522 Registered On : 17-Feb-2026 13:27
Age/Gender : 36 Years / Female Collected On : 17-Feb-2026 13:28
Ref. By : Reported On : 18-Feb-2026 17:01
Patient Location : NURTURE MULTISPECIALITY HOSPITAL IP/OP No. :

LABORATORY TEST REPORT

TEST PARAMETER RESULT UNIT REFERENCE RANGE SAMPLE TYPE

CLINICAL BIOCHEMISTRY
SECOND TRIMESTER PRENATAL SCREENING
Marker AFP 25.34 ng/ml Serum
Method : Chemiluminescence
Marker ESTRIOL (E3) 0.81 ng/ml
Method : Chemiluminescence
Marker Inhibin A 163.80 pg/ml
Method : Chemiluminescence
Beta HCG, Marker 42270 IU/ml .
Method : Chemiluminescence

Note:
• The calculated risk by BENETECH software depends on the accuracy of the information provided by the referring physician. Please note that risk calculations
are statistical approaches and have no diagnostic value.
• The patient combined risk presumes the NT measurement was done according to accepted guidelines. The laboratory cannot be hold responsible for their
impact on the risk assessment. Prenatal screen is not a diagnostic test and a negative test does not necessarily rule out the absence of fetal defects and a
positive test does not confirm Trisomy. Hence a high risk report should be followed by confirmatory tests like chorionic villous sampling (CVS) based on the
clinical history.
• All serum marker multiple of medians are adjusted for maternal weight (to account for dilution effects in heavier mothers). The estimated risk calculations
and screen results are dependent on accurate information for gestation, maternal age and weight. Inaccurate information can lead to significant alternations
in the estimated risk.
• Multiple of the Median (MOM): Analyte values are compared to median values at a given gestational age and multiple of the median (MoM) results obtained.
The MoM results are used in a multivariate algorithm that includes the mother’s age to derive risk factors for Down syndrome and Trisomy 18. An interpretive
report is provided.
• Double marker screen or first ±trimester screen is performed by measuring analytes in maternal serum that are produced by the fetus and the placenta.
Additionally, the Nuchal translucency (NT) measurement is a sonographic marker shown to be effective in screen foetuses for Down syndrome. A
mathematical model is used to calculate risk estimate by combining the analyte values, NT measurement and maternal demographic information.
• PAPP-A is highly expressed in first-trimester trophoblasts, participating in regulation of fetal growth. Levels in maternal serum increase throughout pregnancy.
Low PAPP ±A levels before the 14th week of gestation are associated with an increased risk for Down syndrome and Trisomy 18.
• Nuchal Translucency (NT) measurement, an ultrasound marker is obtained by measuring the fluid-filled pace within the Nuchal region of the fetus. While fetal
NT measurements obtained by ultrasonography increase in normal pregnancies with advancing gestational age, Down’s syndrome foetuses have larger NT
measurements than gestational age-matched normal foetuses. Increased fetal NT measurements can therefore serve as an indicator of an increased risk for
Down’s syndrome.
• Important Note for Multiple fetus: In twin pregnancies with a fetal demise, results may be unreliable. Results are not available for pregnancies with triplets
and high order multiples.

------------------ End Of Report ------------------

Processed By : Automated

[Link] CHETHAN MBBS M.D., Consultant

Biochemist
KMC Reg. No: 41296

Page 1 of 4
Report Status: Final
Outside samples to be correlated with other clinical findings
Name : Mrs. SONAL UH ID :
Lab ID : 26210002522 Registered On : 17-Feb-2026 13:27
Age/Gender : 36 Years / Female Collected On : 17-Feb-2026 13:28
Ref. By : Reported On : 18-Feb-2026 17:01
Patient Location : NURTURE MULTISPECIALITY HOSPITAL IP/OP No. :

LABORATORY TEST REPORT

TERMS & CONDITIONS OF REPORTING

• It is presumed that the specimen belongs to the patient named or identified in the test request form.
• The report results are for information and interpretation for your referring doctor can be correlated with the patient's
clinical history.
• Biological Reference Range/Interval is suggested for your Gender and Age on the basis of available literature. All
reference ranges are to be reconsidered by the doctor’s advice for your specific care.
• Test requested might not be performed for the following reasons
◦ Specimen quality insufficient (inadequate collections/spillage in transit)
◦ Specimen quality unacceptable (haemolysed/clotted/ lipemic etc.)
◦ lncorrect specimen type.
◦ Test cancelled either or request of patient or doctor, or because of incorrect test code, test name of specimen
received. Reference may be provided to a new Accession number. Under "COMMENT" if the specimen has
been re-accessioned for a different test. It is expected that a fresh specimen will be sent for the purpose of
reporting on the same parameter(s), if required.
• This Medical Report is a professional opinion, not a diagnosis. Test results are not valid for medico legal purposes.
• The report will carry the name and age provided at the time of registration. To maintain confidentiality, certain reports
may not be e-mailed at the discretion of the management.
• All the notes and interpretation beneath the test result in the report provided are for educational purposes only. It is not
intended to be a substitute for doctor's consultation.
• Reports that carries a 'PRELIMINARY' status signifies that results are yet to be reported for one or more of the test, or
else as is the case with many microbiology tests, a "FINAL'.' culture, identification or drug susceptibility result might
be pending. In such case, the descriptor "RESULTS" column will be replaced by the test results whenever the latter are
ready. The report will, when completed, acquire a "FINAL'.' status.
• Results of tests may vary from laboratory to laboratory and in some parameters from time to time for the same patients.
Test results and reference range may also vary depending on the technology and methodology used. Laboratory test
results may also vary depending on the age, sex, time of the day sample has been taken, diet, medication and !imitation
of modern technology.
• In case of any unexpected or alarming test results, please contact us immediately for re-confirmation, further discussion,
clarifications and rectifications, if needed only.
• In case of any discrepancy due to typing error, kindly get It rectified immediately. The collection date was not stated in
the Test Requisition Form, the same will not be printed on the report.
• The Lab or its employees/representatives does not assume any liability or responsibility for any loss or damage that may
be incurred by any person as result of interpreting the meaning of this report.
• In case of any issues or suggestions about your test results, please email us on hello@[Link]
• Our liability is limited to the amount of investigations booked with us.
• The courts (forums) at Bengaluru shall have exclusive jurisdiction in all disputes/claims concerning the tests and the
results of the tests.

Page 2 of 4
Report Status: Final
Outside samples to be correlated with other clinical findings
 Second Trimester Prenatal Screening

PATIENT INFORMATION CLINICAL INFORMATION

NAME: MRS, SONAL GESTATIONAL AGE: 16 weeks 1 day from EDD of 03/08/2026
PATIENT CODE: 26210002522 MATERNAL AGE AT TERM: 37.3 years
DOB: 02/04/1989 MATERNAL WEIGHT: 68.5 kg
LMP: 04/11/2025 MATERNAL RACE: India
PHYSICIAN: MATERNAL HISTORY:
GESTATION: Singleton
SCREENING STATUS: Initial sample
SPECIMEN RECEIVED: 17/02/2026
SPECIMEN CODE: TRIDENT DIAGNOSTICS
COLLECTION DATE: 17/02/2026 REPORTED: 18/02/2026

CLINICAL RESULTS
Second Assay MoM DS OSB T18
Trimester Results serum age serum population serum background
screen only screen prevalence screen risk
AFP 25.3 ng/mL 0.81
uE3 0.81 ng/mL 0.75 1:10
hCG 42270.0 IU/mL 0.86
DIA 163.8 pg/ml 0.89
1:100

Risk Assessment (at term) Cutoff

Down Syndrome 1:1490 1:250 1:1000
Age alone 1:253
1:10000
OSB: 1:25900 1:242(2.50 MoMs)
Trisomy 18 1:13000 1:100
1:1490 1:253 1:25900 1:1000 1:13000 1:2530

Interpretation*
DOWN SYNDROME Screen Negative
The risk of Down syndrome is LESS than the screening cut-off. No follow-up is
Note:
. DOWN
OPEN
TRISOMY
The
Comments: SYNDROME
SPINA
18 risk
calculated BIFIDA
by BENETECH software
Screen
indicated dependsthis
Negative
regarding on result.
the accuracy of the information provided by the referring
physician. Please note
OPEN SPINA BIFIDA that risk calculations
The
These are
risk statistical
maternal
serum
of Down
marker
serum approaches
syndrome
AFP
levelsresult
are and
is LESS
not have
is NOT no
thediagnostic
consistent
thanelevated
screening
withforthe value.
[Link]
a pregnancy
pattern oflaboratory
seen
No follow-up
this
in Trisomy
gestational
is
Screen Negative
cannot be hold responsible for their impact on
indicated
age.
18/13 the
The risk
ofassessment.
pregnancies.
regarding
risk an this
open
Maternal Prenatal
result.
neural
serum
tube screen
screening
defect isis not
less
will a diagnostic
detect
than the test
approximately
screening and a negative
cut-off.
60% of
The maternal serum AFP result is NOT elevated for a pregnancy of this gestational
test does not necessarily rule out the absence
Trisomy of fetal pregnancies.
defects and a positive test does not confirm Trisomy. Hence a high
age. The18/13
risk of an open neural tube defect is less than the screening cut-off.
risk report should be followed by confirmatory - amniocentesis.
TRISOMY 18 Screen Negative
These serum marker levels are not consistent with the pattern seen in Trisomy
18/13 pregnancies. Maternal serum screening will detect approximately 60% of
Trisomy 18/13 pregnancies.
Comments:
.

Page 3 of 4
[Link] CHETHAN MBBS., M.D.
KMC [Link]
Printed 18/02/2026 16:49:29 Page 1/2
 Second Trimester Prenatal Screening

PATIENT INFORMATION CLINICAL INFORMATION

NAME: MRS, SONAL GESTATIONAL AGE: 16 weeks 1 day from EDD of 03/08/2026
PATIENT CODE: 26210002522 MATERNAL AGE AT TERM: 37.3 years
DOB: 02/04/1989 MATERNAL WEIGHT: 68.5 kg
LMP: 04/11/2025 MATERNAL RACE: India
PHYSICIAN: MATERNAL HISTORY:
GESTATION: Singleton
SCREENING STATUS: Initial sample
SPECIMEN RECEIVED: 17/02/2026
SPECIMEN CODE: TRIDENT DIAGNOSTICS
COLLECTION DATE: 17/02/2026 REPORTED: 18/02/2026

Note: The calculated risk by BENETECH software depends on the accuracy of the information provided by the referring
physician. Please note that risk calculations are statistical approaches and have no diagnostic value. The laboratory
cannot be hold responsible for their impact on the risk assessment. Prenatal screen is not a diagnostic test and a negative
test does not necessarily rule out the absence of fetal defects and a positive test does not confirm Trisomy. Hence a high
risk report should be followed by confirmatory - amniocentesis.

Page 4 of 4
[Link] CHETHAN MBBS., M.D.
KMC [Link]
Printed 18/02/2026 16:49:29 Page 2/2